<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - EPOETINS</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drugClass/">Drug classes</a></li>
      </ul>

      <h1>EPOETINS</h1>

      <nav>
        <ul class="nav nav-list">

          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#importantSafetyInformation" data-toggle="tab">Important safety information</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#drugsInClass" data-toggle="tab">Drugs in class</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">






      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Patients unable to receive thromboprophylaxis</li>
            <li>pure red cell aplasia following erythropoietin therapy</li>
            <li>uncontrolled hypertension</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Aggravation of hypertension (dose-dependent), cardiovascular events, diarrhoea, dose-dependent increase in platelet count regressing during treatment (but thrombocytosis rare), headache, hypertensive crisis (in isolated patients with normal or low blood pressure), increase in blood pressure (dose-dependent), influenza-like symptoms (may be reduced if intravenous injection given over 5 minutes), nausea, shunt thrombosis especially if tendency to hypotension or arteriovenous shunt complications, vomiting,
              </p>
              <p>
                <strong>veryRare:</strong> Sudden loss of efficacy because of pure red cell aplasia, particularly following subcutaneous administration in patients with chronic renal failure,
              </p>
              <p>
                <strong>notKnown:</strong> Anaphylaxis, angioedema, hyperkalaemia, hypersensitivity reactions, injection-site reactions, peripheral oedema, skin reactions,
              </p>
        
        
            <section class="advice">
                <h3>Hypertensive crisis</h3>
              <p>In isolated patients with normal or low blood pressure, hypertensive crisis with encephalopathy-like symptoms and generalised tonic-clonic seizures requiring immediate medical attention has occured with epoetin.</p>
            </section>
            <section class="advice">
                <h3>Pure red cell aplasia</h3>
              <p>There have been very rare reports of pure red cell aplasia in patients treated with erythropoietins. In patients who develop a lack of efficacy with erythropoietin therapy and with a diagnosis of pure red cell aplasia, treatment with erythropoietins must be discontinued and testing for erythropoietin antibodies considered. Patients who develop pure red cell aplasia should <b>not</b> be switched to another form of erythropoietin.</p>
            </section>
        
      </section>




      <section class="tab-pane" id="importantSafetyInformation">
        <h2>Important safety information</h2>

            <section class="importantSafetyInformation">
                <h3>MHRA/CHM advice (December 2007) Erythropoietins&amp;#8212;haemoglobin concentration</h3>
              <p>Overcorrection of haemoglobin concentration in patients with chronic kidney disease may increase the risk of death and serious cardiovascular events, and in patients with cancer may increase the risk of thrombosis and related complications:</p><ul>
            <li>patients should not be treated with erythropoietins for the licensed indications in chronic kidney disease or cancer in patients receiving chemotherapy <i>unless</i> symptoms of anaemia are present</li>
            <li>the haemoglobin concentration should be maintained within the range 10&#8211;12&#8239;g/100&#8239;mL</li>
            <li>haemoglobin concentrations higher than 12&#8239;g/100&#8239;mL should be avoided</li>
            <li>the aim of treatment is to relieve symptoms of anaemia, and in patients with chronic kidney disease to avoid the need for blood transfusion; the haemoglobin concentration should not be increased beyond that which provides adequate control of symptoms of anaemia (in some patients, this may be achieved at concentrations lower than the recommended range)</li>
            </ul>
            </section>
            <section class="importantSafetyInformation">
                <h3>MHRA/CHM advice (December 2007 and July 2008) Erythropoietins&amp;#8212;tumour progression and survival in patients with cancer</h3>
              <p>Clinical trial data show an unexplained excess mortality and increased risk of tumour progression in patients with anaemia associated with cancer who have been treated with erythropoietins. Many of these trials used erythropoietins outside of the licensed indications (i.e. overcorrected haemoglobin concentration or given to patients who have not received chemotherapy):</p><ul>
            <li>erythropoietins licensed for the treatment of <i>symptomatic</i> anaemia associated with cancer, are licensed only for patients who are receiving chemotherapy</li>
            <li>the decision to use erythropoietins should be based on an assessment of the benefits and risks for individual patients; blood transfusion may be the preferred treatment for anaemia associated with cancer chemotherapy, particularly in those with a good cancer prognosis</li>
            </ul>
            </section>
      </section>

      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Aluminium toxicity (can impair the response to erythropoietin)
          </li>
          <li>
            concurrent infection (can impair the response to erythropoietin)
          </li>
          <li>
            correct factors that contribute to the anaemia of chronic renal failure, such as iron or folate deficiency, before treatment.
          </li>
          <li>
            during dialysis (increase in unfractionated or low molecular weight heparin dose may be needed)
          </li>
          <li>
            epilepsy
          </li>
          <li>
            inadequately treated or poorly controlled blood pressure&#8212;interrupt treatment if blood pressure uncontrolled
          </li>
          <li>
            ischaemic vascular disease
          </li>
          <li>
            malignant disease
          </li>
          <li>
            other inflammatory disease (can impair the response to erythropoietin)
          </li>
          <li>
            risk of thrombosis may be increased when used for anaemia before orthopaedic surgery&#8212;avoid in cardiovascular disease including recent myocardial infarction or cerebrovascular accident
          </li>
          <li>
            risk of thrombosis may be increased when used for anaemia in adults receiving cancer chemotherapy
          </li>
          <li>
            sickle-cell disease (lower target haemoglobin concentration may be appropriate)
          </li>
          <li>
            sudden stabbing migraine-like pain (warning of a hypertensive crisis)
          </li>
          <li>
            thrombocytosis (monitor platelet count for first 8 weeks)
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Monitor closely blood pressure, reticulocyte counts, haemoglobin, and electrolytes&#8212;interrupt treatment if blood pressure uncontrolled.</p>
            </section>
            <section class="patientParameters">
              <p>Other factors, such as iron or folate deficiency, that contribute to the anaemia of chronic renal failure should be corrected before treatment and monitored during therapy. Supplemental iron may improve the response in resistant patients.</p>
            </section>
      </section>











      <section class="tab-pane" id="drugsInClass">
        <h2>Drugs in the class of EPOETINS</h2>

          <ul>
            <li><a href="../drug/PHP5886.html">DARBEPOETIN ALFA</a></li>
            <li><a href="../drug/PHP96719.html">EPOETIN ALFA</a></li>
            <li><a href="../drug/PHP96720.html">EPOETIN BETA</a></li>
            <li><a href="../drug/PHP96722.html">EPOETIN ZETA</a></li>
          </ul>
      </section>

    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
</body>
</html>
